A novel mechanism of action of HER2 targeted immunotherapy is explained by inhibition of NRF2 function in ovarian cancer cells
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: Proliferation of ovarian cancer cell lines in absence or presence of either NAC or RA in growth media. Exponentially growing cells were seeded in 96 well plates in triplicates and allowed to attach for 24 h. Following this, cells were either left untreated (UT) in media containing 5% charcoal stripped FBS, or treated with same media containing 1nM Heregulin (HRG) or with cotreatments of 10mM NAC or 2.5μM RA individually for the indicated time points. MTT reagent was directly added at the end of treatments and cells further incubated for 4 h. The up taken dye was released by adding 100μL of DMSO for 15min and recording absorbance at 540nm using multiplate reader (MODULUS Methprimer (www.urogene.org) was used to analyses 1.5kb NRF2 promoter region for potential CpG islands and methylation prediction. A 270pb stretch of promoter containing 18 CpG dinucleotides was identified for subsequent methylation analysis. (B and C) Agarose gel image of the PCR products from bisulfite converted DNA using bisulfite conversion specific primers. Total genomic DNA was extract from PEO4, OVCAR4 and SKOV3 cells previously either untreated (UT) or exposed to HER2 inhibitors (RTKi) for 96 h. The extracted DNA was quantified, bisulfite converted and subjected to PCR amplification using primers specific to the bisulfite converted DNA and flanking the 270pb region of NRF2 promoter containing the identified 18 CpG dinucleotides.
